HCV eradication does not impact gut dysbiosis or systemic inflammation in cirrhotic patients

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 6, 2016, Pages 638-643

  Bajaj, J S ^a   Sterling, R K ^a   Betrapally, N S ^b   Nixon, D E ^a   Fuchs, M ^a   Daita, K ^a   Heuman, D M ^a   Sikaroodi, M ^a   Hylemon, P B ^a   White, M B ^a   Ganapathy, D ^a   Gillevet, P M ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; INTERLEUKIN 6; PEGINTERFERON; RIBAVIRIN; TELAPREVIR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANEMIA; ARTICLE; BACTERIUM DETECTION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSBIOSIS; ENTEROBACTERIACEAE; FECES ANALYSIS; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; INFLAMMATION; LACHNOSPIRACEAE; LEUKOCYTE COUNT; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTPATIENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOPATHY; RUMINOCOCCACEAE; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS LOAD;

EID: 84981163495     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13732     Document Type: Article

References (31)

1. Younossi ZM, Stepanova M, Nader F, Lam B, Hunt S. The patient's journey with chronic hepatitis C from interferon plus ribavirin to interferon- and ribavirin-free regimens: a study of health-related quality of life. Aliment Pharmacol Ther 2015; 42: 286–95.
2. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C – the impact of liver disease and new treatment regimens. Aliment Pharmacol Ther 2015; 41: 497–520.
3. Younossi ZM, Stepanova M, Mishra A, Venkatesan C, Henry L, Hunt S. The impact of chronic hepatitis C on resource utilisation and in-patient mortality for Medicare beneficiaries between 2005 and 2010. Aliment Pharmacol Ther 2013; 38: 1065–75.
4. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61(1 Suppl.): S58–68.
5. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39: 518–31.
6. Di Marco V, Calvaruso V, Ferraro D, et al. Effects of viral eradication in patients with HCV and cirrhosis differ with stage of portal hypertension. Gastroenterology 2016; 151: 130–9.e2.
7. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013; 158: 329–37.
8. Bajaj JS, Forton DM. Cognitive improvement after HCV eradication: extending the benefits. Hepatology 2013; 58: 480–2.
9. Sack J, Garcia-Tsao G. Variceal hemorrhage in a patient with HCV cirrhosis in whom liver synthetic function had normalized after viral elimination. Hepatology 2016; 63: 1733–5.
10. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virologic response in Veterans with HCV-infection. Hepatology 2016; 64: 130–7.
11. Reig M, Marino Z, Perello C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol 2016; doi: 10.1016/j.jhep.2016.04.008 [Epub ahead of print].
12. Hoofnagle JH. Hepatic decompensation during direct-acting antiviral therapy of chronic hepatitis C. J Hepatol 2016; 64: 763–5.
13. Shawcross DL. Is it time to target gut dysbiosis and immune dysfunction in the therapy of hepatic encephalopathy? Expert Rev Gastroenterol Hepatol 2015; 9: 539–42.
14. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60: 940–7.
15. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26–42.
16. Lin CY, Tsai IF, Ho YP, et al. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007; 46: 816–26.
17. Bajaj JS, Betrapally NS, Gillevet PM. Decompensated cirrhosis and microbiome interpretation. Nature 2015; 525: E1–2.
18. Gillevet P, Sikaroodi M, Keshavarzian A, Mutlu EA. Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers 2010; 7: 1065–75.
19. Hamady M, Knight R. Microbial community profiling for human microbiome projects: tools, techniques, and challenges. Genome Res 2009; 19: 1141–52.
20. http://qiime.org/tutorials/tutorial.html.
21. White JR, Nagarajan N, Pop M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol 2009; 5: e1000352.
22. Rutter K, Stattermayer AF, Beinhardt S, et al. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther 2015; 41: 521–31.
23. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol 2011; 61: 693–703.
24. Mutlu EA, Gillevet PM, Rangwala H, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012; 302: G966–78.
25. Stattermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P. Review article: genetic factors that modify the outcome of viral hepatitis. Aliment Pharmacol Ther 2014; 39: 1059–70.
26. Stattermayer AF, Strassl R, Maieron A, et al. Polymorphisms of interferon-lambda4 and IL28B – effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C. Aliment Pharmacol Ther 2014; 39: 104–11.
27. Bajaj JS, Cox IJ, Betrapally NS, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 2014; 307: G951–7.
28. Leclercq S, Matamoros S, Cani PD, et al. Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol-dependence severity. Proc Natl Acad Sci USA 2014; 111: E4485–93.
29. Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2015; 42: 1051–63.
30. Bajaj JS, Heuman DM, Hylemon PB, et al. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Aliment Pharmacol Ther 2014; 39: 1113–25.
31. Dhiman RK, Rana B, Agrawal S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014; 147: 1327–37 e3.